FOLD icon

Amicus Therapeutics

8.88 USD
+0.25
2.90%
At close Mar 11, 4:00 PM EDT
1 day
2.90%
5 days
-2.52%
1 month
-7.21%
3 months
-12.60%
6 months
-21.21%
Year to date
-4.62%
1 year
-26.79%
5 years
10.31%
10 years
-4.62%
 

About: Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Employees: 499

0
Funds holding %
of 7,363 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

6% more repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 100

2% less call options, than puts

Call options by funds: $4.77M | Put options by funds: $4.87M

7% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 42

2% less funds holding

Funds holding: 287 [Q3] → 282 (-5) [Q4]

5.71% less ownership

Funds ownership: 107.81% [Q3] → 102.1% (-5.71%) [Q4]

16% less capital invested

Capital invested by funds: $3.42B [Q3] → $2.87B (-$541M) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 4 (-2) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$12
35%
upside
Avg. target
$16.67
88%
upside
High target
$21
136%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Wells Fargo
Tiago Fauth
39% 1-year accuracy
11 / 28 met price target
91%upside
$17
Overweight
Maintained
20 Feb 2025
Cantor Fitzgerald
Kristen Kluska
25% 1-year accuracy
26 / 104 met price target
136%upside
$21
Overweight
Reiterated
15 Jan 2025
Morgan Stanley
Jeffrey Hung
57% 1-year accuracy
16 / 28 met price target
35%upside
$12
Equal-Weight
Downgraded
13 Dec 2024

Financial journalist opinion

Based on 14 articles about FOLD published over the past 30 days

Neutral
GlobeNewsWire
5 days ago
In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer
Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al. Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al.
In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer
Neutral
GlobeNewsWire
1 week ago
NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act
Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al.
NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act
Neutral
GlobeNewsWire
1 week ago
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
Negative
Zacks Investment Research
2 weeks ago
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
Positive
Zacks Investment Research
2 weeks ago
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amicus Therapeutics (FOLD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics
Neutral
Business Wire
2 weeks ago
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company's shareholders. Click here for additional information: https://kaskelalaw.com/case/amicus-therapeutics/ Since December 2023, shares of Amicus' common stock have declined in value from a trading price of $14.50 per share to a current trading price of approximately $11.00 per share, a decline of nearly 25% in value. The investigation seeks.
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
Neutral
Seeking Alpha
2 weeks ago
Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President and Chief Executive Officer Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Dennis Ding - Jefferies Joe Schwartz - Leerink Partners Kristen Kluska - Cantor Fitzgerald Malcolm Kuno - JPMorgan Salveen Richter - Goldman Sachs Gil Blum - Needham & Company Jeff Hung - Morgan Stanley Joshua Fleishman - TD Cowen Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Full Year 2024 Financial Results Conference Call and Webcast.
Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
2 weeks ago
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.11 per share a year ago.
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates
Neutral
GlobeNewsWire
2 weeks ago
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J.
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
Neutral
GlobeNewsWire
3 weeks ago
Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amicus Therapeutics, Inc. (NASDAQ: FOLD) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm
Charts implemented using Lightweight Charts™